X-Chem and Kymera Therapeutics have expanded their collaboration, which will now comprise 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration.
With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera – using its DEL platform to support Kymera’s discovery of protein degraders.
Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics, said: “X-Chem has been a valued partner in helping us to unlock challenging disease targets that can be only or best addressed by targeted protein degradation. We look forward to extending our collaboration and working together to discover revolutionary new medicines.”
Matt Clark, CEO of X-Chem, added: “We are delighted to be able to work more closely with Kymera and help them discover more compounds that positively impact patients.”
